Shopping Cart
- Remove All
Your shopping cart is currently empty
CDK9-IN-12
🥰Excellent
Catalog No. T39354Cas No. 1942843-54-0
CDK9-IN-12 is a highly selective CDK9 inhibitor, which is commonly used in leukemia research to regulate oncogene expression, inhibit oncogenic proliferation, and induce apoptosis by targeting CDK9-dependent transcription processes.
CDK9-IN-12
🥰Excellent
Purity: 98.93%
Catalog No. T39354Cas No. 1942843-54-0
CDK9-IN-12 is a highly selective CDK9 inhibitor, which is commonly used in leukemia research to regulate oncogene expression, inhibit oncogenic proliferation, and induce apoptosis by targeting CDK9-dependent transcription processes.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $61 | In Stock | |
| 5 mg | $147 | In Stock | |
| 10 mg | $233 | In Stock | |
| 25 mg | $486 | In Stock | |
| 50 mg | $782 | In Stock | |
| 100 mg | $1,060 | In Stock | |
| 200 mg | $1,430 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CDK9-IN-12"
AT7519
Cited
T6205844442-38-2
AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
- $52
Size
QTY
CitedPalbociclib monohydrochloride
PD 0332991 hydrochloride, Palbociclib hydrochloride, Palbociclib (PD-0332991) HCl
T6239827022-32-2
Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.
- $30
Size
QTY
CASIN
Pirl1-related Compound 2
T3971425399-05-9
CASIN (Pirl1-related Compound 2) is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
- $32
Size
QTY
Abemaciclib methanesulfonate Cited
LY2835219 mesylate, LY2835219 (methanesulfonate), LY2835219, abemaciclib mesylate
T31111231930-82-7
Abemaciclib methanesulfonate (LY2835219) is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM).
- $30
Size
QTY
CitedRibociclib
Cited
LEE011
T61991211441-98-3
Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50:10/39 nM).
- $36
Size
QTY
CitedSeliciclib Cited
R-roscovitine, Roscovitine, CYC202
T2095186692-46-6
Seliciclib (Roscovitine) is a potent inhibitor of Cdk2/cyclin E (IC50=0.1 µM). Seliciclib also inhibits Cdk7/cyclin H, Cdk5/p35 and Cdc2/cyclin B (IC50=0.49/0.16/0.65 µM). Seliciclib has antitumor activity.
- $40
Size
QTY
CitedAbemaciclib Cited
LY2835219, CDK4/6 dual inhibitor
T23811231929-97-7
Abemaciclib (LY2835219) is a dual inhibitor of CDK4/6 (IC50=2/10 nM) with selectivity and specificity. Abemaciclib has antitumor activity and is used to treat advanced or metastatic breast cancer.
- $48
Size
QTY
CitedRafoxanide
T709322662-39-1
Rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer. Rafoxanide is a salicylanilide used as an anthelmintic. It is used to treat fluke, hookworm and other infestations.
- $54
Size
QTY
Dinaciclib Cited
SCH 727965, PS-095760
T1912779353-01-4
Dinaciclib (SCH 727965) is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM). It exhibits potential antitumor activity by inhibiting the incorporation of thoracic glycan (dThd) DNA.
- $47
Size
QTY
CitedGW 441756
T6052504433-23-2
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
- $51
Size
QTY
Ro-3306 Cited
T2356872573-93-8
RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.
- $32
Size
QTY
CitedSodium Oxamate Cited
SO, Oxamic acid sodium salt, oxamate sodium, Aminooxoacetic acid sodium salt
T19831565-73-1
Sodium Oxamate (Oxamic acid sodium salt) is an LDH inhibitor that specifically inhibits LDHA. Sodium Oxamate has antitumor activity and induces cell cycle arrest and apoptosis.
- $31
Size
QTY
CitedSelect Batch
Purity:98.93%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | CDK9-IN-12 is a highly selective CDK9 inhibitor, which is commonly used in leukemia research to regulate oncogene expression, inhibit oncogenic proliferation, and induce apoptosis by targeting CDK9-dependent transcription processes. |
| Targets&IC50 | CDK9-CyclinT1:5.41 nM |
| In vitro | CDK9-IN-12 has an inhibitory effect on the following cells: Mino, Z-138, JeKo-1, Raji, OCI-Ly-10, TMD8, MM.1S, RPMI-8226, Kasumi-1, HL-60, CCRF-CEM, MV-4-11 cells with IC50 values of 8.4, 46, 46, 37, 3.2, 46, 1.5, 5.4, 21, 44, 2.1, 1.6 nM, respectively. [1] |
| In vivo | Methods: CDK9-IN-12 (7.5 mg/kg, 0.5% CMC-Na, gavage, 21 days) was used to treat MV-4-11 cell tumor xenograft model mice. First, PK experiments were performed in mice. Second, the diameter of the transplanted tumor and the weight of the mice were measured twice a week to evaluate the in vivo anticancer effect. Results: CDK9-IN-12 has a long half-life (t1/2 = 8.02 h) and acceptable bioavailability (F = 33.7%). In addition, CDK9-IN-12 can significantly inhibit tumor progression, with a T/C value of 27.80%. [1] |
| Molecular Weight | 378.86 |
| Formula | C21H19ClN4O |
| Cas No. | 1942843-54-0 |
| Smiles | ClC1=C(C=2C=C3C(=CC2)NN=C3C)C=C(N[C@@H](CO)C4=CC=CC=C4)C=N1 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (211.16 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CDK9-IN-12 | purchase CDK9-IN-12 | CDK9-IN-12 cost | order CDK9-IN-12 | CDK9-IN-12 chemical structure | CDK9-IN-12 in vivo | CDK9-IN-12 in vitro | CDK9-IN-12 formula | CDK9-IN-12 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.